Exopharm Limited
EX1.AX
Australian Securities Exchange0.01
AUD
+0.00
- -
Exopharm Limited
EX1.AX
(Australian Securities Exchange)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Exopharm Limited Exopharm Limited (ASX:EX1), formerly focused on exosome-based drug delivery technologies, completed a reverse merger with Tryp Therapeutics Inc. in May 2024, resulting in a name change to Tryptamine Therapeutics Limited and a shift to a clinical-stage biotechnology company developing proprietary psychedelic formulations for neuropsychiatric disorders and chronic pain conditions. The company, founded in 2013 and headquartered in Melbourne, Australia, now advances genetic medicines and exosome-based therapies using extracellular vesicles as non-viral drug delivery chassis; its core products include TRP-8803, an intravenous-infused psilocin formulation designed to reduce psychedelic state duration and improve patient experience in psychotherapy-assisted treatments, and TRP-8802, an oral synthetic psilocybin analog targeting indications such as obesity, fibromyalgia, irritable bowel syndrome-related abdominal pain, and other diseases with unmet needs. Exopharm operates primarily in the biopharmaceutical sector, making proprietary technologies like LEAP manufacturing, LOAD API loading, and EVPS tropism available to pharmaceutical partners; recent strategic changes encompass the CAD 7.2 million reverse acquisition transaction, a A$6.5 million public share offering at A$0.02 per share, ASX re-compliance under new code TYP, completion of Phase Ib dosing for TRP-8803 in obesity trials, and Phase IIa studies with institutions including the University of Michigan and Massachusetts General Hospital, alongside plans to transition positive oral psilocybin outcomes to IV psilocin programs.